In patients with recently diagnosed polymyalgia rheumatica on a 24-week glucocorticoid taper, methotrexate 25 mg/week vs placebo raised glucocorticoid-free remission at 52 weeks (80% vs 46%; risk difference 34%), among 58 of 64 analysed.
RCTn = 64
Bolhuis et al. Results of a 1-year randomised double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica